Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAL-PDT with and without Er:YAG AFL for Actinic Cheilitis
NCT02198469Phase 1Completed
- Sponsor
- Dong-A University
- Start
- Jan 2012
- Primary completion
- Mar 2014
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of methyl aminolevulinate in actinic cheilitis (AC) (2 arms), sponsored by Dong-A University. Primary endpoint: Treatment Efficacy at 12 months. Started Jan 2012; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic cheilitis (AC)
Beyond the preview
Go deeper on NCT02198469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02198469.